DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death

Published:2018-12 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Thibault Benoît,Genre Ludivine,Le Naour Augustin,Broca Clothilde,Mery Eliane,Vuagniaux Grégoire,Delord Jean Pierre,Wiedemann Norbert,Couderc Bettina

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-35860-z.pdf

Reference52 articles.

1. Jemal, A. et al. Global cancer statistics. CA. Cancer J. Clin. 61, 69–90 (2011).

2. Cho, K. R. & Shih, I.-M. Ovarian cancer. Annu. Rev. Pathol. 4, 287–313 (2009).

3. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376–1388 (2014).

4. Balasubramaniam, S., Kim, G. S., McKee, A. E. & Pazdur, R. Regulatory considerations on endpoints in ovarian cancer drug development. Cancer 123, 2604–2608 (2017).

5. Clamp, A. & Jayson, G. PARP inhibitors in BRCA mutation-associated ovarian cancer. Lancet Oncol. 16, 10–12 (2015).

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models;Heliyon;2024-08

2. Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin;Experimental Cell Research;2024-04

3. Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial;Clinical Cancer Research;2024-03-19

4. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design;Future Oncology;2024-01-10

5. Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses;Cellular Immunology;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3